Category: Press Releases

Press Releases

BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline

Aug 20, 2025

VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is...

Continue Reading

Press Releases

BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment

Aug 5, 2025

VANCOUVER, BC / ACCESSWIRE / Aug 5, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT | OTC: BNXTF | FSE: BXT), a bioscience company specializing...

Continue Reading

Press Releases

BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation

Jul 23, 2025

VANCOUVER, BC / ACCESS Newswire / July 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology

Jul 9, 2025

VANCOUVER, BC / ACCESS Newswire / July 8, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in advanced drug-delivery technologies, today...

Continue Reading

Press Releases

API Delivery Initiates Next Phase for BioNxt’s Sublingual Cladribine Multiple Sclerosis Program

Jul 7, 2025

Vancouver, BC – July 7, 2025 – BioNxt Solutions Inc. (CSE: BNXT | OTC: BNXTF | FSE: BXT), a bioscience innovator specializing in advanced drug...

Continue Reading

Press Releases

BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets

Jun 25, 2025

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for...

Continue Reading

Press Releases

BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent

May 23, 2025

VANCOUVER, BC / ACCESS Newswire / May 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory

May 13, 2025

VANCOUVER, BC / ACCESS Newswire / May 13, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization

May 5, 2025

VANCOUVER, BC / ACCESS Newswire / May 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Solutions Prepares for Human Bioequivalence Study For Multiple Sclerosis (MS)

Apr 23, 2025

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities

Jan 21, 2025

VANCOUVER, BC / January 21, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT) (OTC MARKETS: BNXTF) (FSE: BXT), a bioscience company specializing...

Continue Reading

Press Releases

BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP

Dec 19, 2024

VANCOUVER, BC / ACCESSWIRE / December 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems,...

Continue Reading